|Bid||0.287 x 100|
|Ask||0.288 x 4200|
|Day's Range||0.275 - 0.291|
|52 Week Range||0.260 - 3.600|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
When Galena Biopharma Inc (NASDAQ:GALE) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...
On a per-share basis, the San Ramon, California-based company said it had a loss of 15 cents. In the final minutes of trading on Thursday, the company's shares hit 31 cents. A year ago, they were trading ...
While small-cap stocks, such as Galena Biopharma Inc (NASDAQ:GALE) with its market cap of USD $14.97M, are popular for their explosive growth, investors should also be aware of their balanceRead More...
For Galena Biopharma Inc’s (NASDAQ:GALE) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Broadly speaking, thereRead More...
Galena Biopharma Inc will pay more than $7.55 million to resolve charges it paid kickbacks to doctors to induce them to prescribe its opioid-based pain medication Abstral to patients, the U.S. Department of Justice said on Friday. The settlement with Galena comes as federal authorities try to combat an epidemic of opioid abuse, which President Donald Trump last month declared a national emergency.
The San Ramon, California-based company said it had a loss of 22 cents per share. Losses, adjusted to account for discontinued operations and non-recurring costs, were 16 cents per share. In the final ...
What are the top 10 penny stocks to buy in 2017? Out of thousands of stocks that are trading at price levels below $1.00, it can be hard to identify winning picks, especially since it’s no secret that the companies behind penny stocks may be involved in scams or other shady endeavors that will cause […]
AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).
On a per-share basis, the San Ramon, California-based company said it had a loss of 45 cents. Losses, adjusted to account for discontinued operations, came to 9 cents per share. In the final minutes of ...
Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.
Juno Therapeutics Inc. (JUNO) reported first-quarter 2017 loss of 71 cents per share (including stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 66 cents.
Agios Pharmaceuticals, Inc. (AGIO) posted first-quarter 2017 loss of $1.56 per share, narrower than the Zacks Consensus Estimate of a loss of $1.79 but wider than the year-ago loss of 61 cents.
Zacks.com featured highlights: Galena Biopharma, EVINE Live, Sanchez Production Partners, Bazaarvoice and Avon Products
Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).
An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.
Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy
Roche Holding AG’s RHHBY member, Genentech announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of subcutaneous Rituxan /hyaluronidase for the treatment of patients ...
Acorda Therapeutics, Inc. (ACOR) announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson's disease.
Acorda Therapeutics, Inc. ACOR announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson’s disease. CVT-301 is being studied as a self-administered inhaled ...
Amgen Inc. AMGN recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA. The company intends ...
Vertex Pharmaceuticals (VRTX) announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco (ivacaftor) in combination with tezacaftor VX-661 (tezacaftor) in patients suffering from cystic fibrosis.
Vertex Pharmaceuticals Incorporated’s VRTX shares were up almost 19% in pre-market trading after the company announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco ...